Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Save
100711 25 µg ¥6,170
100712 100 µg ¥19,650
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  2. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  3. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  4. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  5. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  6. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  7. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  8. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  9. Guo A, et al. 2022. Nature. 607:135. PubMed
  10. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  11. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  12. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  13. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  14. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  15. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  16. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  17. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  18. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  19. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  20. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  21. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  22. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  23. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  24. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  25. He Y, et al. 2023. Biomolecules. 13:. PubMed
  26. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  27. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  28. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  29. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  30. Li M, et al. 2023. BMC Cancer. 23:497. PubMed
  31. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  32. Lan Y, et al. 2023. iScience. 26:106817. PubMed
  33. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  34. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  35. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  36. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  37. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  38. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  39. Kragten NAM, et al. 2022. Eur J Immunol. 52:389. PubMed
  40. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  41. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  42. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  43. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  44. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  45. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  46. Marié IJ, et al. 2022. Bio Protoc. 12:e4438. PubMed
  47. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  48. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  49. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  50. Theofilatos D, et al. 2022. STAR Protoc. 3:101839. PubMed
  51. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  52. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  53. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  54. Morrow RJ, et al. 2022. Cells. 11: . PubMed
  55. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  56. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  57. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  58. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  59. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  60. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  61. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  62. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  63. Zheng J, et al. 2023. Biomater Res. 27:9. PubMed
  64. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  65. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  66. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  67. Mise Y, et al. 2022. Carcinogenesis. 43:647. PubMed
  68. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  69. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  70. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  71. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  72. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  73. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  74. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  75. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  76. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  77. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  78. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  79. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  80. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  81. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  82. Wang D, et al. 2018. Immunity. 48:659. PubMed
  83. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  84. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  85. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  86. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  87. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  88. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  89. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  90. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  91. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  92. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  93. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  94. Li ZX, et al. 2022. Arch Virol. :. PubMed
  95. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  96. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  97. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  98. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  99. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  100. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  101. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  102. Dong L, et al. 2021. Cancer Cell. . PubMed
  103. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  104. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  105. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  106. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  107. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  108. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  109. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  110. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  111. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  112. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  113. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  114. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  115. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  116. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  117. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  118. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  119. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  120. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  121. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  122. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  123. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  124. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  125. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  126. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  127. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  128. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  129. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  130. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  131. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  132. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  133. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  134. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  135. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  136. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  137. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  138. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  139. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  140. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  141. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  142. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  143. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  144. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  145. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  146. Solanki A, et al. 2018. Development. 145. PubMed
  147. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  148. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  149. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  150. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  151. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  152. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  153. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  154. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  155. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  156. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  157. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  158. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  159. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  160. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  161. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  162. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  163. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  164. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  165. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  166. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  167. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  168. He X, et al. 2021. Small. 17:e2007165. PubMed
  169. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  170. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  171. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  172. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  173. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  174. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  175. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  176. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  177. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  178. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  179. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  180. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  181. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  182. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  183. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  184. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  185. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  186. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  187. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  188. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  189. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  190. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  191. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  192. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  193. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  194. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  195. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  196. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  197. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  198. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  199. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  200. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  201. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  202. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  203. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  204. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  205. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  206. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  207. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  208. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  209. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  210. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  211. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  212. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  213. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  214. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  215. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  216. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  217. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  218. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  219. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  220. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  221. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  222. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  223. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  224. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  225. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  226. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  227. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  228. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  229. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  230. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  231. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  232. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  233. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  234. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  235. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  236. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  237. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  238. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  239. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  240. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  241. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  242. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  243. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  244. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  245. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  246. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  247. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  248. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  249. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  250. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  251. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  252. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  253. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  254. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  255. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  256. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  257. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  258. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  259. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  260. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  261. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  262. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  263. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  264. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  265. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  266. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  267. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  268. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  269. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  270. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  271. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  272. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  273. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  274. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  275. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  276. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  277. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  278. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  279. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  280. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  281. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  282. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  283. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  284. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  285. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  286. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  287. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  288. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  289. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  290. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  291. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  292. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  293. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  294. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  295. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  296. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  297. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  298. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  299. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  300. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  301. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  302. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  303. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  304. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  305. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  306. Chen B, et al. 2021. Cell. 184:6262. PubMed
  307. Smith LK, et al. 2021. Elife. 10:. PubMed
  308. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  309. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  310. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  311. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  312. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  313. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  314. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  315. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  316. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  317. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  318. Zheng Y, et al. 2022. Transl Res. :. PubMed
  319. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  320. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  321. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  322. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  323. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  324. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  325. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  326. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  327. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  328. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account